HAI-ROBOTICS
23.5.2022 10:44:09 CEST | Business Wire | Press release
HAI ROBOTICS, the pioneer in Autonomous Case-handling Robot (ACR) systems for warehouse logistics, will exhibit its cutting-edge automation technology at LogiMAT 2022, Europe's biggest annual intralogistics tradeshow, from May 31 to June 2 in Stuttgart, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220522005089/en/
The company will show how the ACR systems, a highly flexible goods-to-person solution that improves operation efficiency and storage density, could meet the current needs of Europe's warehouses and distribution centers.
The live demo at Booth D71, Hall 3 will be led by HAIPICK A42T, the tallest robot in HAI ROBOTICS' ACR systems that can reach a max picking height of 10-meters. Featuring a telescopic lift, the robot can also descend to as low as 0.28m to pick totes and cartons stored on the bottom level of the shelf. It can carry 8 loads to feed HAIPORT, goods-to-person workstation, in one move. The robot has been titled the "Best in Intralogistics" in IFOY 2021.
HAIPORT, also to be displayed at LogiMAT, is another warehousing efficiency and throughput booster. With the ability to load four to eight cases in only three seconds from a robot, and unload the same number of cases in five seconds at the same time, a single workstation is able to handle up to 900 cases per hour, an order-fulfillment speed that is 16 times faster than robot-to-conveyor belt transport.
ACR systems, "much more attractive"
HAI ROBOTICS sees the ACR systems a good fit for European users, especially in the age of e-commerce when more consumers are longing for faster deliveries and omni-channel shopping experience.
Mr Kai Ramadhin, the company's VP of Sales & Marketing Europe, said: "HAI ROBOTICS solution provides more flexibility in terms of expansion ability, rapid deployment times and so on. So the sweet-spot of our solution is much more attractive."
Mr Ramadhin noted the company is focused on creating a local network of system integrator, installation and service partners, so that any user of ACR systems can expect rapid and high-quality service wherever they are in Europe.
Since setting up its regional headquarters in the Netherlands in late 2021, HAI ROBOTICS has built a strong localized network in countries of France, Germany, Spain, Italy, the Benelux and the U.K.
The ACR systems are presented by its global partner Savoye at Log!Ville in Belgium in an initiative to make the high-density warehousing technology widely known to the European supply chain. The company has also teamed up with U.K.-based Invar System and Greece's Voyatzoglou Systems to enable tailored service accessible to regional business operators.
When the market gets increasingly dynamic and volatile, the company sees the systems can bring users some key benefits, including:
1. Alleviating labor challenges
Through the automation of practices, warehouses can meet the demands of the modern world by improving employee productivity and filling job vacancies, when recruiting and retaining gets tough.
Robots also free workers from doing repetitive and labour intensive work in the warehouse. The ACR systems, for example, save a worker 40,000 to 60,000 steps of walking per day, on average, according to the company's statistics.
2. Storage space utilization to save land investment
As warehouse ceiling heights have continuously risen, the ACR systems, with the max picking height reaching 10 meters, allow the warehouse to easily use the upper storage space. That may also save the user investment in warehouse expansion, in particular in countries where land costs are high.
3. Fast & flexible implementation, more affordable
Business owners are facing a fast-changing and less predictable market nowadays than ever before. The growing customer expectations for faster deliveries and omni-channel shopping experience are driving companies to rethink their supply-chain operating models. The ACR systems have the high level of flexibility to allow a project to be deployed within months, and can be easily scaled according to business volume. A warehouse owner can choose to scale operation by adding or removing robots without disrupting any ongoing operations since the ACR systems require no structural changes to an existing facility.
That also means the systems are more affordable, especially for smaller businesses.
In Europe, many small-to-medium-sized enterprises see a need for automation, but their limited budget does not allow them to spend years implementing large projects. The ACRs turn out to be a fit in that case too.
ACR systems allow any business to start automation small, and grow as business grows. Many of its subscribers started to customize their solutions with a few robots and adding more when their demand expands.
4. Ideal for the age of e-commerce
In the age of e-commerce, businesses across the globe need to deal with flurries of online orders, which often come scattered and in large numbers. Plus the need to shorten delivery time to improve customer satisfaction, they need to significantly boost the order-fulfilment speed of their warehouses and DCs.
E-grocery emerges to be the channel embracing the growth capabilities. According to McKinsey, e-grocery channel grew by more than 50 percent in 2020 - compared to 2019 growth - for key European markets, creating an even stronger need for efficient e-grocery fulfillment solutions. Smaller unit picks, mixed orders, and a high speed of delivery make e-grocery labor intensive and therefore ideal for automation.
The ACR systems can boost order-fulfillment efficiency when handling large SKU portfolio as well as small orders with a high share of single-unit picks in e-grocery warehouses.
In several micro-fulfillment centers in Europe, the ACR systems have been implemented to handle home-delivery orders as well as click-and-collect orders with contactless deliveries over the counter at the storefront.
ABOUT HAI ROBOTICS
HAI ROBOTICS, the pioneer in Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse. The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 in Shenzhen, China, HAI ROBOTICS has offices in the U.S., Europe, Japan, Southeast Asia, Australia, Hong Kong and Taiwan, serving customers from more than 30 countries and regions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220522005089/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
